{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["15(6)"],"submitter":["Arshad A"],"pubmed_abstract":["<h4>Background</h4>Pancreatic cancer is a rapidly progressive disease which is often only amenable to palliative treatment. Few patients respond to palliative chemotherapy, so surrogate markers indicating which patients are likely to respond to treatment are required. There is a well-established link between pro-inflammatory circulating cytokines and growth factors (CAF), and the development of neoplasia. Agents that may modulate these factors are of interest in developing potential novel therapeutic applications.<h4>Methods</h4>As part of a single-arm phase II trial in patients with advanced pancreatic cancer (APC) treated with gemcitabine and intravenous (i.v.) omega-3 rich lipid emulsion (n-3FA), serum samples were analysed for 14 CAF using a multiplex cytokine array. Baseline serum con"],"journal":["HPB : the official journal of the International Hepato Pancreato Biliary Association"],"pagination":["428-32"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3664046"],"repository":["biostudies-literature"],"pubmed_title":["Reduction in circulating pro-angiogenic and pro-inflammatory factors is related to improved outcomes in patients with advanced pancreatic cancer treated with gemcitabine and intravenous omega-3 fish oil."],"pmcid":["PMC3664046"],"pubmed_authors":["Chung WY","Metcalfe MS","Dennison AR","Arshad A","Steward W"],"additional_accession":[]},"is_claimable":false,"name":"Reduction in circulating pro-angiogenic and pro-inflammatory factors is related to improved outcomes in patients with advanced pancreatic cancer treated with gemcitabine and intravenous omega-3 fish oil.","description":"<h4>Background</h4>Pancreatic cancer is a rapidly progressive disease which is often only amenable to palliative treatment. Few patients respond to palliative chemotherapy, so surrogate markers indicating which patients are likely to respond to treatment are required. There is a well-established link between pro-inflammatory circulating cytokines and growth factors (CAF), and the development of neoplasia. Agents that may modulate these factors are of interest in developing potential novel therapeutic applications.<h4>Methods</h4>As part of a single-arm phase II trial in patients with advanced pancreatic cancer (APC) treated with gemcitabine and intravenous (i.v.) omega-3 rich lipid emulsion (n-3FA), serum samples were analysed for 14 CAF using a multiplex cytokine array. Baseline serum con","dates":{"release":"2013-01-01T00:00:00Z","publication":"2013 Jun","modification":"2025-04-04T08:19:34.506Z","creation":"2019-03-27T01:10:25Z"},"accession":"S-EPMC3664046","cross_references":{"pubmed":["23458624"],"doi":["10.1111/hpb.12002"]}}